Tsingke Biotech is a leader in synthetic biology, specializing in AI-driven molecular manufacturing technologies to establish a world-class gene factory. We offer comprehensive services, from raw material production to GMP-grade nucleic acid manufacturing, catering to both research institutions and industrial enterprises.
Our advanced AI-powered platform includes high-throughput oligonucleotide manufacturing, antibody discovery and manufacturing, as well as strain engineering and screening. With over 20 years of expertise, we have earned the trust of more than 300,000 clients worldwide, including academic institutions, biotech companies, diagnostic developers, and pharmaceutical manufacturers.
At Tsingke, we are committed to advancing innovation across research, diagnostics, and therapeutics. By optimizing R&D, production, and commercialization, we empower our partners to accelerate the translation of innovations into scalable, real-world solutions, driving long-term growth in the industry.
Biotech for a Better World — driving scientific innovation through advanced nucleic acid manufacturing.
The Great Tsingke Gene Factory — building the most integrated and efficient global platform for DNA/RNA synthesis.
Founder began entrepreneurial activities in nucleic acid synthesis
Founder began entrepreneurial activities in nucleic acid synthesis
Expanded into chemical raw material production
Expanded into chemical raw material production
Launched professional genetic testing services
Launched professional genetic testing services
Introduced oligonucleotide synthesis and advanced modification capabilities
Introduced oligonucleotide synthesis and advanced modification capabilities
Developed proprietary automated synthesis instruments
Developed proprietary automated synthesis instruments
Expanded operations to molecular reagent production
Expanded operations to molecular reagent production
Incorporated as Beijing Tsingke Biotech Co., Ltd., focusing on gene synthesis services
Incorporated as Beijing Tsingke Biotech Co., Ltd., focusing on gene synthesis services
Secured 150 M CNY Series A funding and entered the protein antibody market
Secured 150 M CNY Series A funding and entered the protein antibody market
Secured 400 M CNY Series B funding and initiated R&D in gene regulation and small nucleic acid therapeutics
Secured 400 M CNY Series B funding and initiated R&D in gene regulation and small nucleic acid therapeutics
Completed joint-stock transformation as Beijing Tsingke Biotech Joint-stock Co., Ltd
Completed joint-stock transformation as Beijing Tsingke Biotech Joint-stock Co., Ltd
Tsingke's operations are strategically distributed
across China to support the Gene Factory concept
Stay updated with the latest industry news and expert insights.
Subscribe now to receive:
● Industry updates
● Exclusive expert insights and analysis
Enter your email to stay ahead!
